TownSquare Capital’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

TownSquare Capital’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,081	Closed	-$7.28K	–	1313
2023 Q4	$7.28K	Hold	1,081	–	–	﹤0.01%	1128
2023 Q3	$9.89K	Hold	1,081	–	–	﹤0.01%	1097
2023 Q2	$22.8K	Hold	1,081	–	–	﹤0.01%	1047
2023 Q1	$29.1K	Hold	1,081	–	–	﹤0.01%	961
2022 Q4	$38.3K	Hold	1,081	–	–	﹤0.01%	917
2022 Q3	$244K	Hold	1,081	–	–	0.01%	645
2022 Q2	$204K	Hold	1,081	–	–	0.01%	660
2022 Q1	$269K	Hold	1,081	–	–	0.01%	613
2021 Q4	$168K	Hold	1,081	–	–	﹤0.01%	689
2021 Q3	$217K	Hold	1,081	–	–	0.01%	652
2021 Q2	$285K	Hold	1,081	–	–	0.01%	507
2021 Q1	$287K	Hold	1,081	–	–	0.01%	483
2020 Q4	$399K	Buy	+1,081	New	+$310K	0.02%	402

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

AWP

Accretive Wealth Partners Parsippany, New Jersey $356M AUM 14.3% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

TownSquare Capital's EIGR Position: Q1 2024 in Review

TownSquare Capital sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2024, closing a stake of 1,081 shares — an estimated $7.28K sold.

TownSquare Capital first reported a position in EIGR in Q4 2020 and held it in 13 quarters. The position peaked at $399K in Q4 2020. 24 funds tracked by Wall St. Rank hold EIGR as of Q1 2024.

TownSquare Capital reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2024 after selling out during the quarter.
TownSquare Capital sold 1,081 Eiger BioPharmaceuticals, Inc. shares in Q1 2024, an estimated $7.28K.
TownSquare Capital first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2020 and held it in 13 quarters.
TownSquare Capital's Eiger BioPharmaceuticals, Inc. position peaked at $399K in Q4 2020.
24 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2024.

Based on TownSquare Capital's 13F filing for Q1 2024, filed 15 May 2024.